Security key
10778Y112
BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW)
CUSIP: 10778Y112
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / *W EXP 02/26/202
- Total 13F shares
- 150,673
- Total 13F value
- $15,137
- Share change
- -306,540
- SEC-reported price per share
- $0.10
- Number of holders
- 7
- Value change
- -$31,484
- Number of buys
- 3
- Number of sells
- 2
Report period
Q1 2025
Institutions
7
Top holders
7
BCTXW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
BriaCell Therapeutics Corp. SEC filings
BriaCell Therapeutics Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 10778Y112
Recent filing periods:
Ownership snapshot
Top reported holders of BCTXW - BriaCell Therapeutics Corp. - *W EXP 02/26/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
3i, LP
Disclosed value leader
Marc Lustig
Comparable rows
1/15
Latest evidence
31 Mar 2025
13D/G
3/4/5
13F
Lead comparable stake: 4.9%
14 rows are not safely comparable across share classes.
13D/G row: 3i, LP
Showing 1-6 of 15 holder rows.
Quick read
3i, LP leads the comparable SEC ownership view at 4.9%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens 3i, LP's linked filing trail.
Comparable ownership
Top 1
3i, LP
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 3i, LP |
13D/G
|
4.9%
Reported 13D/G
· 31 Mar 2025
|
$872,128
190,006 shares
|
-$821,582 | 31 Mar 2025 |
| Marc Lustig |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$5,632,601
3,445,870 shares
mixed-class rows
|
— | 14 May 2024 |
| Jamieson Bondarenko |
3/4/5
Chairman, Director
|
—
denominator unverified
|
$777,940
169,856 shares
|
— | 28 Dec 2022 |
| ARMISTICE CAPITAL, LLC |
13F
Company
|
—
denominator unverified
|
$108,563
375,000 shares
|
— | 31 Dec 2024 |
| Vontobel Holding Ltd. |
13F
Company
|
—
denominator unverified
|
$62,150
110,000 shares
|
— | 31 Dec 2024 |
| William V Williams |
3/4/5
President, CEO, Director
|
—
denominator unverified
|
$57,816
29,802 shares
|
— | 23 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
150,673
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2025 Across Filers
Q4 2025 holders
6
Q1 2025 holders
7
Holder diff
1
| Investor | Q4 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend